NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis $6.30 +0.05 (+0.80%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$6.28 -0.01 (-0.24%) As of 05/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Q32 Bio Stock (NASDAQ:QTTB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Q32 Bio alerts:Sign Up Key Stats Today's Range$6.10▼$6.4550-Day Range$4.54▼$7.3052-Week Range$1.35▼$8.05Volume113,342 shsAverage Volume339,171 shsMarket Capitalization$106.85 millionP/E Ratio2.37Dividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. Read More Q32 Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreQTTB MarketRank™: Q32 Bio scored higher than 80% of companies evaluated by MarketBeat, and ranked 137th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingQ32 Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialQ32 Bio has a consensus price target of $13.00, representing about 106.3% upside from its current price of $6.30.Amount of Analyst CoverageQ32 Bio has only been the subject of 3 research reports in the past 90 days.Read more about Q32 Bio's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($2.12) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is 2.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is 2.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.66.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Q32 Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.42% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 1.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Q32 Bio has recently increased by 70.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.22 News SentimentQ32 Bio has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Q32 Bio this week, compared to 2 articles on an average week.Search Interest4 people have searched for QTTB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,344.00 in company stock.Percentage Held by Insiders40.00% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QTTB Stock News HeadlinesQ32 Bio (QTTB) price target increased by 15.12% to 16.83May 14 at 10:56 PM | msn.comQ32 Bio's (QTTB) Buy Rating Reiterated at HC WainwrightMay 8, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 17 at 1:00 AM | Banyan Hill Publishing (Ad)Regulatory Compliance Risks: Q32 Bio Warns of Internal Control Challenges Under Sarbanes-Oxley and Potential Impact on InvestorsMay 6, 2026 | tipranks.comQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | prnewswire.comQ32 Bio Expands ATM Offering With New $75M ProspectusApril 24, 2026 | tipranks.comQ32 Bio Inc. Common Stock (QTTB) Insider ActivityApril 18, 2026 | nasdaq.comQ32 Bio to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | prnewswire.comSee More Headlines QTTB Stock Analysis - Frequently Asked Questions How have QTTB shares performed this year? Q32 Bio's stock was trading at $3.32 at the beginning of the year. Since then, QTTB shares have increased by 89.8% and is now trading at $6.30. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) released its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.14. When did Q32 Bio IPO? Q32 Bio (QTTB) raised $135 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Who are Q32 Bio's major shareholders? Top institutional shareholders of Q32 Bio include Renaissance Technologies LLC (1.22%) and Cetera Investment Advisers (0.12%). Insiders that own company stock include Jodie Pope Morrison, Shelia M Violette and Paul Alloway. View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Q32 Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/05/2026Today5/17/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 QTTB's financial health is in the Green zone, according to TradeSmith. QTTB has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Price Target for Q32 Bio$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+106.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$2.66 Trailing P/E Ratio2.37 Forward P/E RatioN/A P/E GrowthN/ANet Income$29.82 million Net MarginsN/A Pretax Margin61.86% Return on Equity149.23% Return on Assets34.50% Debt Debt-to-Equity Ratio0.04 Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual Sales$53.74 million Price / Sales1.99 Cash Flow$1.51 per share Price / Cash Flow4.16 Book Value$2.73 per share Price / Book2.31Miscellaneous Outstanding Shares16,960,000Free Float10,174,000Market Cap$106.85 million OptionableN/A Beta-0.05 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:QTTB) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredSpaceX Goes Public. Here's What Happens To Your IRA.When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
